Benfluorex, commonly known as Mediator, a diabetes drug that was widely prescribed as a slimming aid, has been responsible for thousands of hospitalizations and deaths in France before it was withdrawn.
Mahmoud Zureik of the National Institute of Health and Medical Research (Inserm), who co-led the probe, told AFP that around 3,100 people had required hospitalisation during the 33 years during which the drug was sold.
Adverse Drug Reaction and Toxicity Finder
Drugs can cause side effects and toxic reactions. These reactions can be very characteristic for a particular drug. The ''Adverse Effects Finder'' is designed to help clinicians find these effects peculiar to certain drugs.
Advertisement
However, these figures could well be an "underestimate," he said.
The study, appearing in the specialised journal Pharmacoepidemiology & Drug Safety, finetunes an estimate by Zureik in 2010 that the death toll from the scandal was between 1,000 and 2,000.
![Walking for Fitness and Weight Loss]( "Walking for Fitness and Weight Loss")
Mediator, known by its lab name as benfluorex, was initially licensed to reduce levels of fatty proteins called lipids, with the claim that it helped diabetics control their level of blood sugar.
But it also suppressed appetite, which meant it gained a secondary official use to help obese diabetics lose weight.
In fact, it was widely sold on prescription for non-diabetics wanting to slim.
In 2009, Mediator was pulled from the European market amid evidence that it damaged heart valves and caused pulmonary hypertension.
Its French manufacturer, Servier, is being probed on suspicion of dishonest practices and deception.
The new study is an extrapolation based on figures for deaths from faulty heart valves, although not from hypertension, among major users of the drug.
The main data comes from France's national health insurance system, which said that 303,000 patients used Mediator in 2006.
According to Mediator, 145 million packets of Mediator were sold on the French market before the drug was pulled.
The Mediator case came to light after a scandal involving a similar type of anti-obesity drug, fenfluramine, in the late 1990s.
Source: AFP
Advertisement
Mediator, known by its lab name as benfluorex, was initially licensed to reduce levels of fatty proteins called lipids, with the claim that it helped diabetics control their level of blood sugar.
But it also suppressed appetite, which meant it gained a secondary official use to help obese diabetics lose weight.
In fact, it was widely sold on prescription for non-diabetics wanting to slim.
In 2009, Mediator was pulled from the European market amid evidence that it damaged heart valves and caused pulmonary hypertension.
Its French manufacturer, Servier, is being probed on suspicion of dishonest practices and deception.
The new study is an extrapolation based on figures for deaths from faulty heart valves, although not from hypertension, among major users of the drug.
The main data comes from France's national health insurance system, which said that 303,000 patients used Mediator in 2006.
According to Mediator, 145 million packets of Mediator were sold on the French market before the drug was pulled.
The Mediator case came to light after a scandal involving a similar type of anti-obesity drug, fenfluramine, in the late 1990s.
Source: AFP
Weight Loss Pills
A number of weight loss products are available. Some products may be ineffective or they could lead to serious side effects.
Advertisement
 Weight Loss with Hypnosis – Does It Work?Hypnosis indirectly helps with weight loss by altering the consciousness through suggestions and imagery to a more positive state. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.